Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessCommentary

The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward

Michele Maio1,2 email, Hugues JM Nicolay1,2 email, Paolo Ascierto3 email, Filippo Belardelli4 email, Roberto Camerini5 email, Mario P Colombo6 email, Paola Queirolo7 email, Ruggero Ridolfi8 email, Vincenzo Russo9 email, Lucia Anzalone1 email, Ester Fonsatti1 email and Giorgio Parmiani10 email

Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy

Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy

Unit of Clinical Immunology, Istituto Nazionale Tumori "Fondazione Pascale" Naples, Italy

Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy

Clinical Research Unit III, Sigma Tau SpA, Rome, Italy

Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Fondazione Istituto Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy

Department of Medical Oncology A, National Institute for Cancer Research, Genova, Italy

Immunotherapy and Somatic Cell Therapy Unit, Istituto Scientifico Romagnolo per lo studio e la cura dei tumori, Forlì, Italy

Cancer Gene Therapy Unit, Department of Oncology, Scientific Institute S. Raffaele, Milan, Italy

10  Department of Oncology, San Raffaele Scientific Institute, Milan, Italy

author email corresponding author email

Journal of Translational Medicine 2008, 6:8doi:10.1186/1479-5876-6-8

Published: 12 February 2008

Abstract

As for a consolidated tradition, the 5th annual meeting of the Italian Network for Cancer Biotherapy took place in the Certosa of Pontignano, a Tuscan monastery, on September 20–22, 2007. The congress gathered more than 40 Italian leading groups representing academia, biotechnology and pharmaceutical industry. Aim of the meeting was to share new advances in cancer bio-immunotherapy and to promote their swift translation from pre-clinical research to clinical applications. Several topics were covered including: a) molecular and cellular mechanisms of tumor escape; b) therapeutic antibodies and recombinant constructs; c) clinical trials up-date and new programs; d) National Cooperative Networks and their potential interactions; e) old and new times in cancer immunology, an "amarcord". Here, we report the main issues discussed during the meeting.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.